Market capitalization | $10.00k |
Enterprise Value | $16.70m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-73.84m |
Free Cash Flow (TTM) Free Cash Flow | $-73.99m |
Cash position | $17.26m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Evelo Biosciences, Inc.:
1 Analyst has issued a forecast Evelo Biosciences, Inc.:
Sep '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.74 -3.74 |
21%
21%
|
|
EBITDA | -70 -70 |
36%
36%
|
EBIT (Operating Income) EBIT | -74 -74 |
36%
36%
|
Net Profit | -82 -82 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Craig Jalbert |
Founded | 2014 |
Website | www.evelobio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.